Pipeline

At GenCART, we are building a transformative pipeline of next-generation CAR-T cell therapies designed to target both hematologic malignancies and autoimmune disorders. Our mission is to harness the full potential of cellular immunotherapy to create effective, safe, and accessible treatments for patients worldwide.

CAR-T Programs in Oncology

Our oncology pipeline focuses on B-cell malignancies, leveraging advanced chimeric antigen receptor (CAR) designs to selectively target and eradicate cancerous B cells. GenCART’s leading therapeutic candidates include:

  • CD19 CAR-T – targeting the well-established B-cell antigen CD19, highly expressed in aggressive lymphomas and leukemias.
  • CD22 CAR-T – directed against CD22, a complementary target enabling treatment of tumors that escape CD19-directed therapies.
  • Dual CD19/CD22 CAR-T – an innovative construct that simultaneously targets both CD19 and CD22, aiming to reduce relapse rates and improve long-term remission.

These therapies are being developed for multiple indications, including:

  • Large B-Cell Lymphoma (LBCL)
  • Follicular Lymphoma (FL)
  • Mantle Cell Lymphoma (MCL)
  • Chronic Lymphocytic Leukemia (CLL)

Through this targeted approach, GenCART’s goal is to deliver durable responses while minimizing treatment-related toxicities and costs.

Expanding into Autoimmune Disorders

Beyond oncology, GenCART is exploring the groundbreaking potential of CAR-T therapy for autoimmune diseases. By reprogramming a patient’s immune cells to selectively eliminate the aberrant B cells that drive autoimmunity, this approach could provide lasting remission without chronic immunosuppression.

GenCART’s investigational CAR-T programs are being evaluated for several autoimmune conditions, including:

  • Systemic Lupus Erythematosus (SLE)
  • Multiple Sclerosis (MS)
  • Rheumatoid Arthritis (RA)
  • Myasthenia Gravis (MG)
  • Autoimmune Hemolytic Anemia (AIHA)
  • Neuromyelitis Optica Spectrum Disorder (NMOSD)

Our goal is to redefine treatment paradigms for these chronic and often debilitating conditions by restoring immune tolerance at its cellular root.